Dana-farber-cancer Institute Inc.

Alyssa Verano

Nathanael Schiander Gray

Tinghu Zhang

Eric S Fischer

Radoslaw Nowak

Jing Ting Christine Yuan

Guangyan Du

Zhixiang He

Pasi Antero Janne

John M Hatcher

Nathanael S Gray

Katherine Donovan

David A Scott

Jaebong Jang

Michael Eck

Dries De Clercq

Hu Liu

Jamie A Saxon

Eric Wang

Disclosed are immunomodulatory compounds, pharmaceutical compositions containing them, and methods of making and using the compounds to treat diseases and disorders characterized by aberrant protein activity that can be targeted by cereblon.

Immunomodulatory compounds

Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders characterized or mediated by aberrant protein activity.

Small molecule degraders of Helios and methods of use

Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by aberrant protein activity that can be targeted by cereblon.

Bispecific degraders

Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by dysregulated or dysfunctional protein activity that can be targeted by cereblon.

CRBN modulators

The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.

Inhibitors of EGFR and/or HER2 and methods of use

The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role. 

Growing community of inventors

Boston, MA, United States of America

Alyssa Verano